Avicenna.ai

The firm develops AI-powered software that uses deep learning and machine learning to automatically identify, prioritize, and quantify pathologies from CT medical images, alerting clinicians within seconds to accelerate therapeutic decisions. Its product suite, CINA (Catheter-related Infections and thrombosis, Neuro, and Abdomen), includes a range of tools that have received both CE Mark certification in Europe and FDA 510(k) clearance in the US. These tools assist in detecting conditions such as intracranial hemorrhage (CINA-ICH), large vessel occlusion (CINA-LVO), pulmonary embolism (CINA-PE), and aortic dissection (CINA-AD). The company has also developed solutions for incidental findings, like CINA-iPE for unsuspected pulmonary embolism and CINA-VCF for vertebral compression fractures. Additionally, its CINA-ASPECTS tool provides a computer-aided diagnosis (CADx) by assessing the severity of ischemic strokes.

Avicenna.AI operates on an asset-light business model focused on R&D, pursuing growth through commercial partnerships with distributors and leading market actors in the US, Europe, and Asia, including Viz.ai, Canon, and Incepto Medical. This strategy has enabled rapid deployment, with its solutions rolled out to over 140 hospitals in 14 countries by early 2023. The company has secured significant funding to fuel its global expansion and R&D efforts. An initial capital infusion of $2.7 million in 2020 was followed by a Series A round that brought the total investment to nearly $10 million by February 2023, with backing from investors Innovacom and CEMAG Invest.